Is UNII-C045TQL4WP Safe in Breastfeeding
Question
I am a breastfeeding mother and i want to know if it is safe to use UNII-C045TQL4WP? Is UNII-C045TQL4WP safe for nursing mother and child? Does UNII-C045TQL4WP extracts into breast milk? Does UNII-C045TQL4WP has any long term or short term side effects on infants? Can UNII-C045TQL4WP influence milk supply or can UNII-C045TQL4WP decrease milk supply in lactating mothers?
UNII-C045TQL4WP lactation summary
- DrLact safety Score for UNII-C045TQL4WP is 7 out of 8 which is considered Dangerous as per our analyses.
- A safety Score of 7 indicates that usage of UNII-C045TQL4WP may cause toxic or severe side effects in breastfed baby.
- Our study of different scientific research indicates that UNII-C045TQL4WP may cause moderate to high side effects or may affect milk supply in lactating mother.
- Our suggestion is to use safer alternate options rather than using UNII-C045TQL4WP .
- Usage of UNII-C045TQL4WP is in contradiction to breastfeeding hence if it is must to use UNII-C045TQL4WP and there is no better alternative available then breastfeeding shall be stopped permanently or temporarily.
- Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.
Answer by Dr. Ru: About UNII-C045TQL4WP usage in lactation
Psychostimulant drug that is used as an anorectic in the treatment of obesity. With similar action than Dexamphetamine. It can cause insomnia, anorexia and nervousness. At latest update no published data were found on excretion into breast milk.Pharmacokinetic data make it likely the passage into milk in an amount that may be significant. Breastfeeding women usually regain their body weight, previous to pregnancy, sooner than those who do not breastfeed. Given the increased risk for cardiac valvular disorders and psychotic reactions, the European Medicines Agency (EMA) ordered the withdrawal from marketing in the European Union on 2000.
Alternate Drugs for Antiobesity preparations. ATC A08
Orlistat(Low Risk)
Sibutramine(Unsafe)
Anfepramone(Dangerous)
Benfluorex-Hcl(Dangerous)
Dexfenfluramine(Unsafe)
Ephedrine(Low Risk)
Fenfluramine(Unsafe)
Phenylpropanolamine(Unsafe)
Phentermine(Dangerous)
Rimonabant(Unsafe)
Ephedrine Hydrochloride(Low Risk)
Ephedrine Sulfate(Low Risk)